Expert Insight: 10 Burning Questions in the Management of Colorectal Cancer
Hematology-Oncology
Credits:
0.75 AMA PRA Category 1 Credit(s) ™
0.75 AMA PRA Category 1 Credit(s) ™
Launch Date:
April 22, 2014
April 22, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Oncologists, Oncology Nurses, Oncology Pharmacists
Relevant Terms:
Colorectal Cancer
Johanna C. Bendell, MD
Johanna C. Bendell, MD
Director, GI Oncology Research
Sarah Cannon Research Institute
Nashville, TN
Bio
Johanna C. Bendell, MD, has been Director of GI Cancer Research at Sarah Cannon Research Institute since February 2008 and serves as its Associate Director of Drug Development. She received her Undergraduate and Medical Degrees from the University of Chicago. Dr. Bendell completed her internship and residency in the Department of Internal Medicine at Brigham and Women's Hospital in Boston, MA., as well as a fellowship in adult oncology at Boston's Dana-Farber Cancer Institute. After finishing her training, Dr. Bendell served as an Assistant of Medicine at Massachusetts General Hospital and instructor in medicine at Harvard Medical School. Dr. Bendell is a Member of the American Society for Clinical Oncology and the American Medical Association. Dr. Bendell is board certified in internal medicine and medical oncology.
John L. Marshall, MD
John L. Marshall, MD
Chief, Division of Hematology/Oncology, MedStar Georgetown University Hospital
Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center
Washington, DC
Bio
John Marshall, MD, is a global leader in the research and development of drugs for colon cancer and other GI cancers. He is the principal investigator of over 150 clinical trials at both the local as well as national levels. Dr. Marshall is the clinical director of oncology for Georgetown University Hospital, associate director for clinical care of the Lombardi Comprehensive Cancer Center, and chief of the Division of Hematology-Oncology. He is widely published in the field of clinical oncology, reviews manuscripts for eight journals, and holds peer-reviewed grants from the National Institutes of Health.
S. Yousuf Zafar, MD, MHS
S. Yousuf Zafar, MD, MHS
Assistant Professor of Medicine
Division of Medical Oncology, Department of Medicine
Duke University School of Medicine
Durham, NC
Bio
Dr. Yousuf Zafar obtained his medical degree from the Medical College of Ohio and his post-graduate training in Internal Medicine from the University of Cincinnati. He completed his fellowship in Hematology/Oncology at Duke University Medical Center. He also completed a Fellowship in Heath Services Research and obtained a Master of Health Science in Clinical Research. Dr. Zafar is an Assistant Professor in the Division of Medical Oncology at Duke University Medical Center. Dr. Zafar is clinically focused on treating gastrointestinal malignancies. His research focuses on how characteristics of patients, providers, and care delivery systems impact the quality of cancer care, the cost of care, as well as the relationship between clinical practices and outcomes. Dr. Zafar's research also focuses on improving quality of life among cancer survivors and those being actively treated for cancer.
| 1. | Summarize emerging safety and efficacy data from pivotal trials of novel targeted therapies used alone or in combination with chemotherapy for the treatment of mCRC (metastatic colorectal cancer) | 2. | Explain the utility of continuing anti-angiogenesis therapy with subsequent lines of therapy post progression |
| 3. | Identify at least three biomarkers commonly being included in CRC (colorectal cancer) clinical trial analyses |
| 1. | Summarize emerging safety and efficacy data from pivotal trials of novel targeted therapies used alone or in combination with chemotherapy for the treatment of mCRC (metastatic colorectal cancer) |
| 2. | Explain the utility of continuing anti-angiogenesis therapy with subsequent lines of therapy post progression |
| 3. | Identify at least three biomarkers commonly being included in CRC (colorectal cancer) clinical trial analyses |
Instructions on How to Receive Credit
- Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
- Complete the post-test and evaluation.
- After passing the post-test, print out your electronic CE certificate.
- In order to successfully complete this activity learners must achieve a minimum of 65% on the post-test.
This activity is supported by unrestricted educational grants from Genentech.
This activity is sponsored by the Institute for Continuing Healthcare Education.
This activity is sponsored by the Institute for Continuing Healthcare Education.
Accreditation Statements
Physicians
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Institute for Continuing Healthcare Education designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
It is the policy of the Institute to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All persons in control of content must disclose any significant financial interest or other relationships that may affect the content of this activity.
Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.
Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.
Faculty
Johanna Bendell, MD
Director, GI Oncology Research
Sarah Canon Research Institute
Nashville, TN
Dr. Bendell has disclosed that she has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
John L. Marshall, MD
Chief, Divison of Hematology/Oncology, MedStar Georgetown University Hospital
Associate Director, Clinical Research, Lombardi Comprehensive Cancer Center
Washington, DC
Dr. Marshall has disclosed the following relevant finanical relationships that have occurred within the past 12 months: Amgen, Bayer, Genentech and Onyx Pharmaceuticals/C, G, H, PE, SB.
S. Yousuf Zafar, MD, MHS
Assistant Professor of Medicine
Duke Cancer Institute
Durham, NC Dr. Zafar has disclosed the following relevant finanical relationships that have occurred within the past 12 months: Genentech/C.
Content Peer Reviewer
Todd M. Bauer, MD
Todd M. Bauer, MD
Investigator, Drug Development and Lung Cancer Research
Sarah Cannon Research Institute
Nashville, TN
Dr. Bauer has disclosed that he does not have any relevant f nancial relationships specific to the subject matter of the content of the activity.
Activity Development and Management Team
Cathy Pagano, CCMEP; Scott Kober, MBA, CCMEP; Sandra Davidson; and Megan Small are employees of the Institute for Continuing Healthcare Education (the Institute) and have no relationships to disclose.
Cathy Pagano, CCMEP; Scott Kober, MBA, CCMEP; Sandra Davidson; and Megan Small are employees of the Institute for Continuing Healthcare Education (the Institute) and have no relationships to disclose.
Off-label Product Disclosure
This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
For additional technical support, please send an email to msmall@iche.edu.
General Disclosure and Copyright Statement
The opinions expressed in this publication are those of the participating faculty and not those of the Institute, Genentech, or any manufacturers of products mentioned herein.
This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.
Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.
Copyright 2014. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.
General Disclosure and Copyright Statement
The opinions expressed in this publication are those of the participating faculty and not those of the Institute, Genentech, or any manufacturers of products mentioned herein.
This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.
Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.
Copyright 2014. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.
